glp-1 agonist and dpp-4 inhibitor Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD GLP-1 receptor agonists or DPP-4
Description
Hamann CR, Chung C, Kaffenberger BH

We compared GLP-1RAs with SGLT2 inhibitors and metformin and found that GLP-1RAs significantly reduced the incidence of major CVEs and mortality rate compared with metformin and second- or third-line glucose-lowering medications
69705-5/asset/079012c9-a24f-4391-ba39-2f5d03668f6f/main.assets/gr1_lrg.jpg)
Neumiller, Mindy M

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet
